BICO Group Q2 2025 slides reveal steep revenue decline, Lab Automation challenges

BICO Group AB reported a challenging Q2 2025, with net sales falling to SEK 324 million, a 17% negative organic growth, and an adjusted EBITDA of SEK -49 million, leading to a 21.58% stock decline. The significant underperformance was primarily driven by a 58% organic contraction in the Lab Automation segment due to project delays and fewer starts, despite relative stability in Life Science Solutions. The company is responding with an action plan for its Biosero unit and recently completed the $80 million divestment of MatTek and Visikol, aiming to strengthen its balance sheet and refocus on lab automation amidst persistent macroeconomic headwinds impacting the life sciences sector.

Analysis

BICO Group AB's Q2 2025 results revealed a severe deterioration in financial performance, triggering a 21.58% decline in its stock price. The company reported a 17% negative organic growth with net sales falling to SEK 324 million, and a negative adjusted EBITDA of SEK -49 million, yielding a -15% margin. The primary driver of this underperformance was a catastrophic failure within the Lab Automation segment, which saw a 58% contraction in organic growth and an adjusted EBITDA margin of -116%, largely due to project execution delays and a SEK 40 million negative impact from re-estimating hours at its Biosero subsidiary. In stark contrast, the Life Science Solutions segment demonstrated resilience with 1% organic growth and a 7% adjusted EBITDA margin. Strategically, BICO is divesting its MatTek and Visikol units for USD 80 million to sharpen its focus on lab automation and strengthen its balance sheet, which showed SEK 636 million in cash reserves at quarter-end despite a negative operating cash flow of SEK -28 million. While management has initiated a comprehensive action plan for Biosero, the company's recovery is contingent on successful execution amidst persistent macroeconomic headwinds, including NIH funding cuts and tariff uncertainties that continue to suppress industry-wide capital investment.

Key Decisions for Investors

• Investors should closely monitor management's execution of the Biosero action plan, as a successful turnaround in the Lab Automation segment is the most critical catalyst for the stock.
• Given the negative operating cash flow of SEK -28 million and significant EBITDA loss, it is crucial to scrutinize the company's quarterly cash burn rate to assess the adequacy of its financial runway, even with the proceeds from the recent divestment.
• The recent divestment simplifies the business, but investors must weigh the high execution risk of the turnaround against the potential long-term value of a more focused lab automation company trading at a depressed valuation.
• Consider the persistent macroeconomic risks, such as NIH funding levels and tariff impacts, as these external factors could significantly hinder BICO's recovery prospects irrespective of internal improvements.